Analysts Set Blueprint Medicines Corporation (BPMC) Price Target at $32.31

Shares of Blueprint Medicines Corporation (NASDAQ:BPMC) have been assigned a consensus rating of “Buy” from the ten ratings firms that are covering the company. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $32.31.

A number of analysts have commented on BPMC shares. Wedbush restated an “outperform” rating and set a $41.00 price target (down previously from $43.00) on shares of Blueprint Medicines Corporation in a research note on Tuesday, November 29th. Zacks Investment Research upgraded shares of Blueprint Medicines Corporation from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a research note on Monday, December 12th. Cowen and Company restated a “buy” rating on shares of Blueprint Medicines Corporation in a research note on Thursday, November 3rd. JMP Securities reiterated a “buy” rating on shares of Blueprint Medicines Corporation in a research note on Thursday, December 1st. Finally, Jefferies Group LLC initiated coverage on shares of Blueprint Medicines Corporation in a research note on Wednesday, December 14th. They issued a “buy” rating and a $40.00 target price for the company.

COPYRIGHT VIOLATION WARNING: “Analysts Set Blueprint Medicines Corporation (BPMC) Price Target at $32.31” was originally published by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark law. The original version of this piece can be read at http://sleekmoney.com/analysts-set-blueprint-medicines-corporation-bpmc-price-target-at-32-31/1656346.html.

In related news, major shareholder Kevin P. Starr sold 106,489 shares of the stock in a transaction dated Monday, December 19th. The shares were sold at an average price of $28.19, for a total transaction of $3,001,924.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Rock Ventures Ii L.P. Third sold 1,000,000 shares of the stock in a transaction dated Tuesday, February 7th. The shares were sold at an average price of $35.28, for a total transaction of $35,280,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,106,689 shares of company stock valued at $38,287,929. 3.93% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of BPMC. Dumont & Blake Investment Advisors LLC bought a new position in Blueprint Medicines Corporation during the third quarter valued at $267,000. Russell Investments Group Ltd. bought a new position in Blueprint Medicines Corporation during the fourth quarter valued at $305,000. UBS Asset Management Americas Inc. raised its position in Blueprint Medicines Corporation by 9.1% in the third quarter. UBS Asset Management Americas Inc. now owns 11,015 shares of the company’s stock valued at $327,000 after buying an additional 915 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in Blueprint Medicines Corporation by 87.9% in the second quarter. Metropolitan Life Insurance Co. NY now owns 15,566 shares of the company’s stock valued at $315,000 after buying an additional 7,281 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in Blueprint Medicines Corporation during the third quarter valued at $554,000. Institutional investors own 59.39% of the company’s stock.

Shares of Blueprint Medicines Corporation (NASDAQ:BPMC) opened at 35.17 on Thursday. The firm’s market cap is $959.89 million. Blueprint Medicines Corporation has a 1-year low of $13.27 and a 1-year high of $38.33. The stock’s 50 day moving average is $32.43 and its 200-day moving average is $29.41.

Blueprint Medicines Corporation (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.62) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.17. The business earned $6.16 million during the quarter, compared to analyst estimates of $6.06 million. Blueprint Medicines Corporation had a negative net margin of 270.30% and a negative return on equity of 55.22%. Blueprint Medicines Corporation’s quarterly revenue was up 79.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.47) EPS. Analysts expect that Blueprint Medicines Corporation will post ($2.74) earnings per share for the current year.

Blueprint Medicines Corporation Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

5 Day Chart for NASDAQ:BPMC

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/analysts-set-blueprint-medicines-corporation-bpmc-price-target-at-32-31/1656346.html

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *